SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgae157 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Yi-Hsin Chan und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Cardiovascular Department, Chang Gung Memorial Hospital at Linkou, Taoyuan City 333, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Atrial Fibrillation, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Ministry of Science and Technology, Taiwan, Chang Gung Memorial Hospital, Linkou.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
The coexistence of diabetes mellitus and atrial fibrillation (AF) is associated with substantial risks of adverse cardiovascular events.
Objective
The relevant outcomes associated with the use of a sodium–glucose cotransporter-2 inhibitor (SGLT2i) vs glucagon-like peptide-1 receptor agonists (GLP-1RAs) among patients with type 2 diabetes (T2D) with/without concomitant AF remain unknown.
Methods
In this nationwide retrospective cohort study from the Taiwan National Health Insurance Research Database, there were 344 392 and 31 351 patients with T2D without AF, and 11 462 and 816 T2D patients with AF treated with SGLT2is and GLP-1RAs, respectively, from May 1, 2016, to December 31, 2019. Patients were followed from the drug index date until the occurrence of study events, discontinuation of the index drug, or the end of the study period (December 31, 2020), whichever occurred first. We used propensity score–stabilized weight to balance covariates across the 2 medication groups.
Results
The incidence rate of all study outcomes in patients with concomitant AF was much higher than in those without concomitant AF. For the AF cohort, SGLT2i vs GLP-1RA was associated with a lower risk of hospitalization for heart failure (HF) (2.32 vs 4.74 events per 100 person-years; hazard ratio [HR] 0.48, 95% CI 0.36-0.66), with no benefit seen for the non-AF cohort (P for homogeneity < .01). SGLT2i vs GLP-1RA was associated with a lower risk of composite kidney outcomes both in the AF (0.38 vs 0.79 events per 100 person-years; HR 0.47; 95% CI 0.23-0.96) and the non-AF cohorts (0.09 vs 0.18 events per 100 person-years; HR 0.53; 95% CI 0.43-0.64). There were no significant differences in the risk of major adverse cardiovascular events and all-cause mortality in those who received SGLT2i compared with GLP-1RA for the AF or non-AF cohorts.
Conclusion
Considering the high risk of developing HF and/or high prevalence of concomitant HF in patients with concomitant diabetes and AF, whether SGLT2is should be the preferred treatment to GLP-1RAs for such a high-risk population requires further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Cardiovascular Department, Chang Gung Memorial Hospital at Linkou, Taoyuan City 333, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan City 333, Taiwan.
- School of Traditional Chinese Medicine, College of Medicine, Chang-Gung University, Taoyuan City 333, Taiwan.
- Microscopy Core Laboratory, Chang Gung Memorial Hospital at Linkou, Taoyuan City 333, Taiwan.
- Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
- Institute of Clinical Medicine, Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
ORCID-Profile: Yi-Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, Lai-Chu See
Förderung
- Ministry of Science and Technology, Taiwan
- Chang Gung Memorial Hospital, Linkou
Zitieren
APA
Chan, Y. H., Chao, T. F., Chen, S. W., Lee, H. F., Li, P. R., Yeh, Y. H., Kuo, C. T., See, L. C., & Lip, G. Y. H. (2024). SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae157
Vancouver
Chan YH, Chao TF, Chen SW, Lee HF, Li PR, Yeh YH, et al. SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae157
BibTeX
@article{Chan2024,
author = {Chan, Yi-Hsin and Chao, Tze-Fan and Chen, Shao-Wei and Lee, Hsin-Fu and Li, Pei-Ru and Yeh, Yung-Hsin and Kuo, Chi-Tai and See, Lai-Chu and Lip, Gregory Y H},
title = {SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgae157}
}
EUVIMED